Sudden death risk stratification in non-ischemic dilated cardiomyopathy using old and new tools: a clinical challenge

Area of Science:

• Cardiology
• Electrophysiology
• Cardiovascular Imaging

Background:

• Risk stratification for sudden cardiac death (SCD) in non-ischemic dilated cardiomyopathy (NIDCM) is a significant clinical challenge.
• Current guidelines rely on left ventricular ejection fraction (LVEF), NYHA class, and QRS duration for device management (ICD/CRT).
• Recent studies and meta-analyses confirm the survival benefit of device therapy in NIDCM, despite some controversy.

Purpose of the Study:

• To review current and emerging risk stratification tools for SCD in NIDCM.
• To propose an individualized approach for device implantation based on novel risk markers.
• To present a practical algorithm for risk stratification and device management in NIDCM patients across different LVEF thresholds.

Main Methods:

• Review of existing literature on risk stratification in NIDCM.
• Inclusion of novel diagnostic modalities such as cardiac magnetic resonance imaging (CMR) for myocardial fibrosis assessment.
• Integration of electrophysiology study (EPS) and genetic testing for risk identification.

Main Results:

• Late gadolinium enhancement on CMR shows promise for improved risk stratification.
• Electrophysiology studies (EPS) and genetic testing are emerging as valuable tools, particularly for familial NIDCM.
• An individualized approach incorporating CMR, EPS, and genetics may refine device management, especially in patients with LVEF > 35%.

Conclusions:

• A combination of traditional markers and newer tools (CMR, EPS, genetics) can enhance risk stratification in NIDCM.
• These advanced methods offer further guidance for device implantation, particularly in challenging cases with preserved LVEF.
• An integrated approach and proposed algorithm can optimize patient selection for cardioverter defibrillator (ICD) and cardiac resynchronization therapy (CRT).